Company intelligence / Profile preview

Shenzhen Haibin Pharmaceutical

Shenzhen, Guangdong, Chinaszhaibin.com ↗

Ownership: Private
Employees: ~500
Development stage: Commercial

Overview

Shenzhen Haibin Pharmaceutical is a leading Chinese manufacturer of carbapenem antibiotics (notably meropenem), exporting APIs and finished dosage forms globally. Its products meet international pharmacopeia standards and have been granted multiple patents for proprietary production processes[3][5][7].

Therapeutic areas: Infectious DiseasesPulmonologyImmunologyCardiovascular
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

1 asset

meropenem

Commercial

Indications: Bacterial infections

Partnerships

Taijing Biotechnology (for TG-1000, anti-influenza, via parent company)Quanxin Bio (anti-TSLP mAb, via parent company)Boan Bio (anti-IL-4Ra mAb, via parent company)

Beyond the preview

Go deeper on Shenzhen Haibin Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Haibin Pharmaceutical.

Explore the full profile